Cipla Limited

U & I Pharmaceuticals, Ltd.

Cipla (UK) Limited

Cipia Limited

Byron Fine Chemicals Inc.

Geena Malhotra

Kalpana Sanjay Joshi

Amar Lulla

Jeevan Ghosalkar

Sarabjit Singh

Dhiraj Abhyankar

Shrinivas Madhukar Purandare

Dharmaraj Ramachandra Rao

Karl Roberts

Srinivas Laxminarayan Pathi

Manish Gopaldas Gangrade

Nandan Kulkarni

Preeti Raut

Anirban Mallik Thakur

Ravichandra Bhadravathi Vedamurthy

Manjinder Singh Phull

Xerxes Rao

Venkata Srinivas Pullela

Vinod Parameshwaran Acharya

Abhijit Jadhav

Pankaj Omprakash Pathak

Harshad Kishore Shete

Brinder Ahluwalia

Ravikumar Puppala

Ashwini Amol Sawant

Venkata Sriram Pullela

Venugopalarao Chinimilli

Shashirekha Kanathala

Y K Hamied

Ramesh Devarapalli

Ramanaiah Chennuru

Ashok Mithun

Mohnish Jagdish Zaveri

Pavan Shewale

Atul Daroi

Siddharth Agrawal

Vipul Mittal

Kalindi Gandhi

Suryanarayana Durga Yarra

V G Nayak

Dinakaran Govindasamy

Vidur Malhotra

Lulla Amar

Nagarjuna Reddy Vantadou

Vrinda Mhapsekar

Shrinivas Purandare

A pharmaceutical composition for inhalation comprising R (+) budesonide and one or more bronchodilators, and, optionally, one or more pharmaceutically acceptable excipients is described.

Pharmaceutical compositions

The present invention discloses novel crystalline polymorphic forms of Acalabrutinib, methods of preparation, pharmaceutical compositions and methods of therapeutic treatment involving polymorphic forms thereof.

Polymorphs of Acalabrutinib, a Bruton's tyrosine kinase inhibitor

The present invention relates to the formulation of midazolam. In particular, the invention provides new midazolam formulation for intranasal administration. These formulations contain midazolam in a high concentration from about 1% to about 10% w/w of the formulation and process of preparation thereof.

Intranasal formulation

An adherence-monitoring and tracking device captures usage of a metered dose inhaler (MDI). The device includes an enclosure for enclosing a metered dose inhaler (MDI), and an electro-mechanical system forming a part of enclosure to sense and log the operation of the MDI. The electro-mechanical system includes at-least one transducer to capture one or more parameters pertaining to an operation of the MDI by the user. A microcontroller processes the captured parameters, and an output-unit renders data pertaining to operation of the MDI.

Adherence-tracking and monitoring device for metered-dose inhaler

The invention relates to pharmaceutical compositions comprising ((((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(phenoxy)phosphoryl)oxy)methyl pivalate or a pharmaceutically acceptable derivative thereof, optionally with an additional agent, methods of making them, and their use in medicine.

The present subject matter refers a blister-strip based dispenser () comprising a lever arm rotatable on receiving a user-actuation. A chassis () is provided for supporting placement of at least one blister-strip () in the form of the coil. The blister-strip () comprises medicament-pockets at at-least one side of the blister-strip (). A plurality of interconnected-rollers () comprises at-least one roller linked to the lever-arm and rotatable by the lever arm. The plurality of interconnected rollers () are configured for anchoring the blister-strip () from one end for enabling the placement in a coil-form and unwinding of the blister strip () from the coil-form, guiding at least two split-portions of the blister-strip (), anchoring an end of each of said at-least two portions of the blister-strip () for winding the at-least two portions separately, and anchoring an end of a lid-foil peeled off the at least two portions for winding the lid-foil.

Single blister-strip based dispenser

An oral or injectable pharmaceutical composition is provided for treating diseases caused by retroviruses or hepatitis B viruses. The composition comprises a therapeutically effective amount of at least one anti-retroviral drug and a therapeutically effective amount of at least one pharmacokinetic booster or enhancer or derivative thereof. Methods and kits are also provided.

A pharmaceutical long acting depot composition is provided as an aid to smoking cessation treatment. The formulation comprises a therapeutically effective amount of varenicline or its pharmaceutically acceptable derivative and pharmaceutically acceptable excipients. The process of preparation of the formulation is also provided.

Depot formulation

Disclosed herein are compositions and methods for the treatment of pulmonary hypertension, including pulmonary arterial hypertension. The methods include administering to a patient in need thereof an effective amount of Quetiapine or derivative thereof. The compositions include an effective amount of Quetiapine or derivative thereof, in some instances combined with one or more additional agents for the treatment of pulmonary hypertension.

Method of treating hypertension

A flow-sensing arrangement within a spirometer. The arrangement includes a tubular-member for allowing an air-passage along a longitudinal-axis thereof. At-least two disc-shaped air-resistive elements are removably-arranged within the tubular member to resist the air-flow. Each of the resistive-elements include perforations for allowing the air-passage through the resistive-element. At-least two ports extend radially outward through a wall of the tubular member, such that each of the two ports are located within the tubular-member near the resistive-elements to cause determination of at least a pressure-difference there-between.

Flow sensing arrangement for spirometer and method thereof

The present invention relates to certain acid salts of (((1-(6-amino-9H-purin-9-yl)propan-2-yloxy)methyl)(phenoxy) phosphoryloxy)methyl pivalate of Formula (I), to processes for their preparation; to pharmaceutical compositions comprising such compounds, and methods of treating a disease which responds to inhibition of nucleotide reverse transcriptase activity.

Salts of antiviral phosphonate analogues and process for preparation thereof

A pharmaceutical composition is provided comprising combination of antiretroviral drugs optionally in combination of pharmacokinetic boosters. The formulation is used for the treatment of diseases caused by retroviruses. The process of preparation of the formulation is also provided.

Combination therapy for use in treating retroviral infections

A pharmaceutical composition is provided for the treatment of systemic infections as well as colonic diseases. The composition comprises a therapeutically effective amount of rifaximin and a therapeutically effective amount of at least one alkaloid or derivative thereof. Methods and kits are also provided.

Pharmaceutical compositions comprising rifaximin

Methods of treating bladder cancer using terconazole are disclosed herein. Terconazole can be administered as part of a comprehensive treatment program, which can also include chemotherapy, immunotherapy, radiation therapy and/or surgical treatment.

Method for the treatment of bladder cancer

Disclosed herein are methods of treating cancers by administration of a PAR-4 agonist.

PAR-4 agonists for the treatment of cancer

Growing community of inventors

Mumbai, India

Geena Malhotra